

Fax completed form to: 1-866-868-0858
Questions, please call: 1-866-316-6049



Important Information About Prescription Drug Coverage

To: _____ From: _____

Fax: _____ Pages: _____

Re: Raptiva® (efalizumab): Prior Authorization Request Form: Please respond.

- Please complete the attached Raptiva® (efalizumab) Prior Authorization Request Form
- To expedite the review process please complete all requested fields.
- Completed forms should be faxed to: 1-866-868-0858. It is not necessary to fax this cover page.

Please note: By signing the attached form you are certifying that the treatment requested is medically necessary. No contraindications are present and precautions have been considered. You will be supervising the patient's treatment. Supporting documentation is available in the patient's record. Signature on this form attests to the fact that the corresponding ICD-9 code has been documented in the patients chart and submitted on a CMS- 1500 form.

Information about this drug

Raptiva® (efalizumab)

In clinical trials Raptiva® resulted in a greater than or equal to a 75% improvement on the Psoriasis Area and Severity Index (PASI-75) after 12 weeks of therapy in only 27% to 39% of patients. The low efficacy of Raptiva® should be weighed against the potential risks (e.g., infection, thrombocytopenia, malignancy) in the elderly.

You can make an expedited request by indicating this at the top of the attached form. If you request an expedited review, and sign the attached form, you certify that applying the 72 hour standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

Information on the attached form is protected health information and subject to all privacy and security regulations under HIPAA.

MemberHealth, LLC, PO Box 391197, Solon OH 44139-3911 Last Updated: 01/17/2008
M0018_PATEMP_1107 CMS 11/28/07 H5656

Prior Authorization Request Form



Fax completed form to 1-866-868-0858 Need help? Call 1-866-316-6049

Patient Information

Name _____
 Member ID _____
 Medicare ID _____
 Date of birth _____ Sex: M / F
 Address _____
 City _____
 State _____ ZIP _____
 Phone _____
 Nursing home resident? YES / NO
 Home care patient? YES / NO

Prescriber and Pharmacy Information

Name _____
 Specialty _____
 DEA _____
 NPI _____
 Address _____
 City _____
 State _____ ZIP _____
 Phone _____ Fax _____
 Pharmacy name _____
 NCPDP _____
 NPI _____
 Phone _____ Fax _____

All items below this line are for Physician Use Only

Information for Requested Drug

Strength: _____ Dosage form: _____ Qty per 30 days: _____ Drug is (circle one): Newly prescribed/Refill
 Directions: _____ Diagnosis: _____ ICD-9 Code: _____

Standard Reviews will be completed in under 72 hours. An expedited review is available if you certify that a standard review timeframe will seriously jeopardize the health of your patient. To request an expedited review, simply indicate this at the top of this page.

Raptiva® (efalizumab) Criteria

- Please indicate Raptiva®'s dispensing location:
 the pharmacy
 the physician's supply, incident to a physician's visit
 other: _____
- Please indicate the patient's diagnosis. Select or specify the correct ICD-9 code. This question must be completed
 moderate to severe chronic plaque psoriasis diagnosed for at least a year (ICD-9: 696.1)
 other (diagnosis and ICD-9) _____
- Is greater than or equal to 10% of the body surface area affected by plaque psoriasis?
 Yes No
- Is the prescribing physician a dermatologist or has a dermatologist been consulted?
 Yes No
- Does the patient have a history of malignancy, a serious current infection or a history of recurrent infections?
 Yes No
 If Yes, please specify: _____
- Has the patient failed to receive a clinically appropriate therapeutic response OR demonstrated intolerance (e.g., allergy, hypersensitivity, adverse effects(s), development

of a contraindication) from at least one systemic DMARD medication (acitretin, methotrexate, cyclosporine) AND at least one topical antipsoriasis medication (e.g. corticosteroid, Dovonex®, Tazorac®, anthralin) over a period of 30 or more days for each drug?
 Yes No

Medical justification: (Attach additional page if necessary): _____

Prescriber's signature: _____ Date: _____